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Abstract
Background: Blastocystis spp. are among the most frequently observed intestinal parasites in humans. Despite the
discovery of Blastocystis approximately 100 years ago, limited information is available regarding its pathogenesis,
genetic diversity, and available treatment options. The aim of this study was to describe the epidemiological and
clinical characteristics of patients with Blastocystis sp. infections diagnosed at Vall d’Hebron University Hospital
(Barcelona, Spain).
Methods: A retrospective observational study was performed which included all adult patients who attended Vall
d’Hebron University Hospital from February 2009 to March 2014 that had Blastocystis sp. detected in their stool.
Results: Four hundred eighteen patients were included, the median age was 36 (18–86) years and 236 (56.5 %)
were men. Regarding patient symptoms, 234 (56 %) patients were completely asymptomatic, 92 (22 %) patients
had symptoms, and 92 (22 %) patients had symptoms that could be attributed to other causes. Of the 92 patients
with symptoms not attributable to other etiologies except for Blastocystis infection, the most frequent symptoms
were diarrhea (61 patients, 66.3 %) and abdominal pain (34 patients, 37 %). Additionally, nine (9.8 %) patients had
cutaneous manifestations. Thirty-one (7.4 %) patients received specific treatment for Blastocystis infection. The
clinical response of treated patients was varied. Five patients experienced complete resolution of symptoms, 12
patients reported improvement of clinical symptoms, eight patients described no clinical improvement, and
information was unavailable for six patients.
Conclusions: Blastocystis infection was detected in 418 patients, most of them foreign-born. Although the vast
majority of patients were asymptomatic, 22 % of patients had gastrointestinal symptoms or cutaneous manifestations
in the absence of other causes. Despite the scarce information available, given the safety of antiparasitic treatment, and
the percentage of patients who experienced resolution or improvement of symptoms, treatment should be considered
in patients with chronic symptoms.
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Background
Parasitic diseases are amongst the most important
causes of morbidity and mortality worldwide, and it is
estimated that nearly 340 parasite species infect humans.
Of these species intestinal protozoa are the most preva-
lent [1]. The pathogenicity of several intestinal protozoa
is well established, and their presence is usually associ-
ated with diarrhea and other intestinal manifestations
(viz. Giardia duodenalis, Entamoeba histolytica, Cryp-
tosporidium spp., Cystoisospora belli). Some protozoa
cause significant morbidity and sometimes mortality,
especially among immunosuppressed populations [2].
In contrast, the role of other intestinal protozoa in the
development of human disease is not well established,
and their presence in both symptomatic and asymptom-
atic patients is difficult to explain [1]. Blastocystis spp.
are among the most frequently observed intestinal para-
sites in humans. Despite its description approximately
100 years ago, little information is available regarding
their pathogenesis, genetic diversity, host range and
available treatment options [3]. Blastocystis has a world-
wide distribution, with higher prevalences reported in
developing countries. The parasite is transmitted by the
fecal-oral route, and animal reservoirs include chickens,
rats and pigs [4]. Seventeen subtypes (STs) have been
described based on analyses of the small subunit rRNA
(SSU rRNA) gene. Only STs 1–9 have been found in
humans, ST-3 being the most prevalent in epidemio-
logical studies [5, 6].
Clinical manifestations associated with Blastocystis
spp. carriage include diarrhea, abdominal pain, vomiting
and other gastrointestinal symptoms. Cutaneous mani-
festations (urticaria) may also be associated with the
presence of Blastocystis spp. [7]. Nevertheless, some in-
vestigators report no association between the presence
of clinical manifestations and Blastocystis infection [8].
Hence, more information is required to properly assess
the potential pathogenicity of this parasite.
Few studies have investigated the prevalence of Blasto-
cystis infection in Spain, and most of them focused on
children or symptomatic patients [9–11]. The aim of the
present study was to describe the epidemiological and
clinical characteristics of adult patients with Blastocystis
infection and evaluate possible risk factors associated
with the presence of clinical manifestations.
Methods
A retrospective observational study was performed at the
Vall d’Hebron University Hospital, a tertiary hospital in-
cluded in the International Health Program of the Catalan
Health Institute (PROSICS Barcelona, Spain). The study
included all adult patients (≥18 years old) who attended
the hospital from February 2009 to March 2014, had Blas-
tocystis spp. in their stool and medical records available.
To establish the study cohort, a list of patients infected
with Blastocystis sp. was compiled by examination of the
Microbiology Department registry. Next, medical records
were reviewed and for those patients with a medical
record available, the following data was collected: epi-
demiological data (age, gender, country of origin, previous
travels), immune status, clinical symptoms that could be
related with Blastocystis sp. infection (gastrointestinal and
cutaneous), detection of other intestinal parasites, treat-
ment received and follow-up after treatment. Blastocystis
sp. detection was performed by microscopic examination
of stool samples following concentration using the
Ritchie’s formalin-ether technique.
According to the geographical origin of patients and
recent travels, patients were classified into four epi-
demiological risk groups: immigrants, travelers (patients
born in Spain who have traveled outside the country in
the last year before their Blastocystis sp. infection), “visit-
ing friends and relatives” (VFR, immigrants living in
Spain who have traveled to their country of origin in
the last year before their Blastocystis sp. infection), and
autochthonous infections (patients born in Spain with
no history of recent travel outside the country).
To identify risk factors associated with the presence of
symptoms, patients were classified into three groups:
asymptomatic patients, symptomatic patients, and
patients with symptoms that could be attributable to
causes other than Blastocystis sp. infection.
In patients who received specific treatment for their
Blastocystis sp. infection, microbiological and clinical
follow-up information was collected. Regarding clinical
response to therapy, patients were classified into three
groups: those who experienced complete resolution of
symptoms, those who reported an improvement in their
symptoms but not complete resolution, and patients
who experienced no clinical improvement following
treatment.
Categorical data are presented as absolute numbers
and proportions, and continuous variables are expressed
as medians and ranges. The χ2 test or Fisher’s exact test,
when appropriate, was used to compare the distribution
of categorical variables, and the Mann-Whitney U-test
for continuous variables. To evaluate the seasonality of
the infection, the two-sample test of proportions was
performed between seasons. Results were considered
statistically significant if the 2-tailed P-value was < 0.05.
SPSS software for Windows (Version 19.0; SPSS Inc,
Chicago, IL, USA) was used for statistical analyses.
Results
After consulting the Microbiology Department registry,
510 possible cases of Blastocystis sp. infection were iden-
tified. After discarding patients less than 18 years old,
duplicated patients, and patients lacking complete
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medical records, 418 cases remained for inclusion in the
study (see Fig. 1). The epidemiological characteristics of
patients are summarized in Table 1. The median age of
patients was 36 (18–86) years, and 236 (56.5 %) were
men. Regarding immigration status, 263 (62.9 %) pa-
tients were immigrants with median time of residence in
Spain of 60 (1–480) months, 26 (6.2 %) patients were
travelers, 10 (2.4 %) patients were VFR, and 119 (28.5 %)
cases were autochthonous. Most patients were diagnosed
in spring, although this difference was not statistically
significant when compared to Blastocystis sp. infections
diagnosed in winter (32.3 vs 22.2 %, Z = 1.66, P = 0.08),
summer (32.3 vs 22 %, Z = 1.69, P = 0.09), and autumn
(32.3 vs 23.4 %, Z = 1.48, P = 0.13).
Sixty-six (15.8 %) patients were immunocompromised.
Forty-three patients had HIV infection, with a median of
CD4+ cell count of 428 (100–1,053) cells/mm3 at the
time their Blastocystis sp. infection was diagnosed, 11
patients had a solid tumor or a haematological malignancy,
and 12 patients had rheumatological, gastrointestinal or
dermatological diseases requiring immunosuppressive
treatment.
Regarding patient symptoms, 234 (56 %) patients were
completely asymptomatic, 92 (22 %) patients had symp-
toms, and 92 (22 %) patients had symptoms that could
be attributed to other causes. Information on the clinical
characteristics of this cohort is available in Table 2.
Among patients with other etiologies that could be re-
sponsible for their symptoms, ten had been diagnosed
with intestinal neoplasm, 24 patients with other infectious
diarrhea (Clostridium difficile, Campylobacter jejuni,
Salmonella enteritidis, Shigella disenteriae, Giardia
duodenalis), six patients with inflammatory bowel dis-
ease, and 11 patients with irritable bowel syndrome.
Other intestinal parasites found in the study population
are described in Table 3. From the 92 patients with
symptoms not attributable to etiologies other than
Blastocystis sp. infection, the duration of symptoms
was < 1 month in 32 (34.8 %) patients, and > 1 month in
60 (65.2 %) patients. The most frequent symptoms were
diarrhea (61 patients, 66.3 %) and abdominal pain (34 pa-
tients, 37 %), and 9 (9.8 %) patients had cutaneous mani-
festations including eczematous or urticarial dermatitis.
When comparing the clinical and epidemiological
characteristics of the asymptomatic and symptomatic
patients with symptoms attributable to Blastocystis sp.
alone, asymptomatic patients were younger (median age
34 years vs 42.5 years, Z = -3.896, P < 0.0001), included a
larger proportion of migrants (89.7 vs 32.6 %, χ2 =
110.998, df = 1, P < 0.0001), and included a greater pro-
portion of immunocompromised patients (20.1 vs 5.4 %,
χ2 = 10.573, df = 1, P = 0.001) (Table 4).
Overall, 31 (7.4 %) symptomatic patients received spe-
cific treatment for Blastocystis sp. infection: 27 patients
received 750 mg metronidazole three times a day for
10 days, two received 800 mg/160 mg cotrimoxazole
two times a day for 7 days, and two patients received
sequential treatment with metronidazole and cotrimoxa-
zole (10 days of 750 mg metronidazole followed by 7 days
of 800 mg/160 mg cotrimoxazole). The clinical response
Fig. 1 Flow diagram depicting study cohort size and selection
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to treatment varied in this group. Five patients experi-
enced complete resolution of symptoms and 12 reported
some clinical improvement but not complete resolution
of their illness. Eight patients described no clinical
improvement following treatment, and information on
the efficacy of treatment was not available for six
patients. Therefore, more than 50 % of treated patients
reported resolution or improvement of symptoms. Stool
examination following treatment was performed for 12
patients. Microbiological cure was observed in seven
patients, and five patients still had Blastocystis sp. in
their stool. Six patients that experienced microbio-
logical cure were treated with metronidazole, and one
had received cotrimoxazole. Four of these patients re-
ported improvement or resolution of symptoms and
three patients reported no clinical improvement.
Discussion
We retrospectively studied 418 adult patients with Blas-
tocystis sp. infection who attended the Vall d’Hebron
University Hospital. Most of them were young (median
age of 36 years), and foreign-born (> 60 % of patients
were born in a country different from Spain). Most of
the patients were asymptomatic, but 22 % of them pre-
sented with symptoms that were most likely attributable
to Blastocystis sp. infection given the absence of any
other potential etiology.
Table 2 Clinical characteristics of patients with Blastocystis sp.
infection attended in Vall d’Hebron University Hospital,
Barcelona (2009–2014)
Characteristics Number of patients (%)
(n = 418)
Presence of immunosuppression 66 (15.8)
HIV infection 43 (10.3)
Oncohaematological disease 11 (2.6)
Rheumatological disease 6 (1.4)
Other immunosuppressant conditions 6 (1.4)
Clinical groups according presence of symptoms
Asymptomatic patients 234 (56)
Symptomatic patients 92 (22)
Symptomatic patients with other
possible explanation
92 (22)
Symptoms among symptomatic patients (n = 92)a
Duration of symptoms
< 1 month 32 (34.8)
> 1 month 60 (65.2)
Diarrhea 61 (66.3)




Abdominal distension 13 (14.1)
Pyrosis 4 (4.3)
Cutaneous manifestations 9 (9.8)
aExcluding symptomatic patients with other possible explanations
Table 1 Epidemiological characteristics of patients with
Blastocystis sp. infection attended in Vall d’Hebron University
Hospital, Barcelona (2009–2014). Data are reported as
number (%) of patients or median (range)
Characteristics Number of patients (n = 418)
Age, years 36 (18–86)
Gender, male 236 (56.5 %)
Origin of patients
Spain 143 (34.2 %)
Latin America 149 (35.6 %)
Sub-Saharan Africa 98 (23.4 %)
Asia 14 (3.3 %)
North Africa 11 (2.6 %)
Other European countries 3 (0.7 %)
Epidemiological risk group
Immigrants 263 (62.9 %)
Autochthonous 119 (28.5 %)
Travelers 26 (6.2 %)
Visiting friends and relatives 10 (2.4 %)
Table 3 Other intestinal parasites observed in stool samples of
the study population
Parasites isolated Number of patients (%)
(n = 418)
Pathogenic parasites
Strongyloides stercoralis 24 (5.7)
Giardia duodenalis 17 (4)
Hookworms 10 (2.4)
Trichuris trichiura 8 (1.9)
Schistosoma mansoni 3 (0.7)
Schistosoma intercalatum 2 (0.5)
Hymenolepis nana 2 (0.5)
Taenia sp. 2 (0.5)
Ascaris lumbricoides 1 (0.2)
Parasites of minor importance
Dientamoeba fragilis 68 (16.2)
Entamoeba histolytica/dispar 3 (0.7)
Non pathogenic parasites
Endolimax nana 66 (15.8)
Entamoeba coli 52 (12.4)
Iodamoeba butschlii 1 (0.2)
Chilomastix mesnili 1 (0.2)
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Interest in Blastocystis sp. has significantly grown in
recent years, due to its potential role as a human pathogen
[3]. The prevalence of Blastocystis sp. infection varies
depending on the study setting, reaching the highest per-
centages (68–100 %) among children from developing
countries [12, 13]. Few studies have been performed in
Spain, and most involve children with prevalences ranging
from 5–20 % [9, 10]. In a previous study carried out by our
group among foreign-born HIV infected adult patients, the
prevalence of Blastocystis sp. infection was 17.3 % [14].
Seasonal distribution of Blastocystis sp. infection was
reported previously in the United Kingdom, with higher
incidences observed in summer [15]. In our study, al-
though the number of cases was higher in spring, this was
not statistically significant. A previous study performed in
the same geographical area (Catalonia, Spain) also showed
no seasonal differences [11].
In the present study, the most frequent symptoms ob-
served in patients with illness that could only be attribut-
able to Blastocystis sp. infection were diarrhea, abdominal
pain, dyspepsia, flatulence and vomiting, similar to other
studies [3]. While its pathogenicity has been questioned,
Blastocystis sp. is now thought to cause gastrointestinal
symptoms under some circumstances, sometimes of a
severe nature [16, 17]. Although less common, cutaneous
manifestations have been reported. In some patients acute
or chronic urticaria has been observed, unexplained by
other causes, with resolution of symptoms described fol-
lowing antiparasitic treatment [18, 19]. Nine patients in our
study presented urticarial dermatitis without a reasonable
cause, except for Blastocystis sp. infection. Some suggest
that cutaneous symptoms may be caused by disruptions in
immune homeostasis as the host produces an inflammatory
response against the amoeboid forms of the parasite [20].
It has been suggested that gastrointestinal symptoms
could be related with the ST of the parasite, but this
remains uncertain [6]. ST-1 seems to be the most
pathogenic one, while ST-3, although being the most
common ST in humans, is less frequently associated
with symptoms [6, 21]. Parasite loads as observed by
light microscopy may also be related to the presence or
absence of symptoms, with symptoms occurring more
frequently when more than five parasites per high-
power field (400×) are observed [22].
Blastocystis sp. infection may cause symptoms similar
to those attributed to irritable bowel syndrome (IBS).
Several studies have shown the possible link between
Blastocystis sp. infection and IBS, and Blastocystis sp. in-
fections are more prevalent among patients with IBS
when compared to control groups [23, 24]. While this is
the case, links between IBS and any particular Blastocys-
tis sp. ST have not been observed [25, 26]. A study by
Nourrisson et al. revealed that patients with IBS and
Blastocystis sp. infection had significantly lower levels
of beneficial gut bacteria including Bifidobacterium
spp. and Faecalibacterium prausnitzii, supporting that
Blastocystis sp. might be linked to the pathophysiology
of IBS and intestinal flora imbalance [27]. In our cohort
of Blastocystis sp. infected patients, 11 had been diag-
nosed with IBS, although only one patient received
antiparasitic treatment and clinical improvement was
not observed. Nevertheless, this association between
IBS and Blastocystis sp. requires further investigation
given the conflicting reports on this subject [28].
In the present study, the asymptomatic patient group
had a higher proportion of foreigners and immunosup-
pressed patients compared to the symptomatic patient
group. These differences could be linked to biases re-
lated to the types of patients that are screened for bowel
parasites, because fecal microscopic examination for in-
testinal parasitosis is routinely performed in our hospital
on immigrants, particularly those who are immunocom-
promised regardless of whether they are symptomatic
or asymptomatic. Information on the pathogenicity of
Blastocystis sp. in immunocompromised patients is
unavailable and only limited information on its preva-
lence in immunosuppressed cohorts has been reported,
mostly for HIV infected patients [14, 29, 30].
Only 31 symptomatic patients received antiparasitic
treatment for Blastocystis sp. infection in our study,
making it difficult to speculate on the usefulness of
treatment for Blastocystis sp. infections. Given the con-
troversy surrounding the pathogenic potential of this
parasite, physicians are still uncertain as to the value of
treating Blastocystis sp. infections. Metronidazole is the
most frequently administered drug for Blastocystis sp.
infection, though its efficacy is highly variable [3]. Other
studies have shown the potential benefits of other drugs,
Table 4 Comparison of clinical and epidemiological characteristics between symptomatic and asymptomatic patients with Blastocystis
sp. infection attended in Vall d’Hebron University Hospital (2009–2014). Data are reported as number (%) of patients or median (range)
Asymptomatic patients (n = 234) Symptomatic patientsa (n = 92) P–value
Age, years 34 (18–84) 42.5 (18–84) < 0.0001
Gender, male 140 (59.8 %) 49 (53.3 %) 0.280
Foreign origin 210 (89.7 %) 30 (32.6 %) < 0.0001
Immunosuppressant condition 47 (20.1 %) 5 (5.4 %) 0.001
aExcluding symptomatic patients for other reasons
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such as nitazoxanide, paromomycin or trimethoprim-
sulfamethoxazole [31, 32]. Despite all the controversies,
the treatment success rate achieved in this study (more
than 50 %), suggest that treatment should be considered
in patients with chronic symptoms in the absence of
other reasonable causes.
This study has some limitations derived from its retro-
spective nature. Among these limitations is the fact that
information retrieved from medical records is not always
complete, different physicians were involved in the diag-
nosis, and differences exist in the way patients were
assessed. Diagnosis was based on the microscopic exam-
ination of stool samples, lacking information relating to
the STs or parasite burden. Moreover, the formalin-ether
technique has reduced sensitivity in detecting Blastocys-
tis sp. compared to other techniques which may have re-
duced its recovery in this cohort [15]. Finally, the small
sample size and the varied responses to chemotherapy
make it difficult to assess the efficacy of antiprotozoal
treatment in this cohort.
Conclusions
In summary, 418 Blastocystis sp. infected patients were di-
agnosed in Vall d’Hebron University Hospital over a 5-year
period, most of them were foreign-born patients (> 60 %).
Although the vast majority of patients were asymptomatic,
22 % of patients had gastrointestinal symptoms or cutane-
ous manifestations in the absence of other potential etiolo-
gies. Despite the scarcity of information available, and
given the safety of antiparasitic treatment, the results of
the present study suggest that antiprotozoal treatment
should be considered in patients infected with Blastocystis
sp. experiencing chronic symptoms. The present study also
suggests that Blastocystis sp. are pathogenic at least under
some circumstances, and should be considered a cause of
illness in the absence of any other etiology.
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